Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
3TR: a pan-European cross-disease research consortium aimed at improving personalised biological treatment of asthma and COPD.
Porsbjerg C, Maitland-van der Zee AH, Brusselle G, Canonica GW, Agusti A, Faner R, Vogelmeier CF, Nawijn M, van den Berge M, Rusconi F, Pilette C, Ramiconi V, Coleman C, Chaudhuri R, Chung KF, Wedzicha J, Saglani S, Van der Schee MP, Heaney L, Bourdin A, Roberts G, Djukanovic R, Kuna P, Kupczyk M, Axmann J, Staudinger H, Clarke GW, Dahlen SE, Brightling C. Porsbjerg C, et al. Among authors: axmann j. Eur Respir J. 2021 Oct 21;58(4):2102168. doi: 10.1183/13993003.02168-2021. Print 2021 Oct. Eur Respir J. 2021. PMID: 34675035 Free article. No abstract available.
Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.
Maher TM, Corte TJ, Fischer A, Kreuter M, Lederer DJ, Molina-Molina M, Axmann J, Kirchgaessler KU, Samara K, Gilberg F, Cottin V. Maher TM, et al. Among authors: axmann j. Lancet Respir Med. 2020 Feb;8(2):147-157. doi: 10.1016/S2213-2600(19)30341-8. Epub 2019 Sep 29. Lancet Respir Med. 2020. PMID: 31578169 Free article. Clinical Trial.
Pirfenidone Treatment in Individuals with Idiopathic Pulmonary Fibrosis: Impact of Timing of Treatment Initiation.
Maher TM, Lancaster LH, Jouneau S, Morrison L, Lederer DJ, Molina-Molina M, Bendstrup E, Kirchgaessler KU, Gilberg F, Axmann J, Petzinger U, Noble PW. Maher TM, et al. Among authors: axmann j. Ann Am Thorac Soc. 2019 Jul;16(7):927-930. doi: 10.1513/AnnalsATS.201810-720RL. Ann Am Thorac Soc. 2019. PMID: 30950636 Free PMC article. Clinical Trial. No abstract available.
Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: design of a double-blind, randomised, placebo-controlled phase II trial.
Maher TM, Corte TJ, Fischer A, Kreuter M, Lederer DJ, Molina-Molina M, Axmann J, Kirchgaessler KU, Cottin V. Maher TM, et al. Among authors: axmann j. BMJ Open Respir Res. 2018 Sep 4;5(1):e000289. doi: 10.1136/bmjresp-2018-000289. eCollection 2018. BMJ Open Respir Res. 2018. PMID: 30233802 Free PMC article.
Relevance of the TAPSE/PASP ratio in pulmonary arterial hypertension.
Tello K, Axmann J, Ghofrani HA, Naeije R, Narcin N, Rieth A, Seeger W, Gall H, Richter MJ. Tello K, et al. Among authors: axmann j. Int J Cardiol. 2018 Sep 1;266:229-235. doi: 10.1016/j.ijcard.2018.01.053. Int J Cardiol. 2018. PMID: 29887454
16 results